Postinfectious irritable bowel syndrome

Gastroenterology

Volumn 124, Issue 6, 2003, Pages 1662-1671

  Spiller, Robin C ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTIBIOTIC AGENT; BILE SALT; BISMUTH; COLESTYRAMINE; DESIPRAMINE; LOPERAMIDE; OPIATE; PAROXETINE; PREDNISOLONE; PROBIOTIC AGENT; SEROTONIN; SEROTONIN ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ANIMAL EXPERIMENT; CELIAC DISEASE; CLINICAL TRIAL; COLITIS; COLON CANCER; CROHN DISEASE; DIET THERAPY; FAMILY HISTORY; GASTROENTERITIS; HUMAN; HYPOCHONDRIASIS; INFECTION; IRRITABLE COLON; LACTOSE INTOLERANCE; LIFE EVENT; LOW FAT DIET; MALABSORPTION; MENTAL DISEASE; META ANALYSIS; MOUSE; NAUSEA; NEUROSIS; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; SEDATION; SEROTONIN RELEASE; SEX DIFFERENCE; SIDE EFFECT; T LYMPHOCYTE;

EID: 0037854783     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00324-X     Document Type: Review

References (72)

1. Longstreth GF, Hawkey CJ, Ham J, Jones RH, Mayer EA, Naesdal J, Wilson IK, Peacock RA, Wiklund K. Demographic and clinical characteristics of patients with irritable bowel syndrome (IBS) from three practice settings. Gastroenterology 2000;118:A146.
2. Boulton-Jones R, Spiller RC. Significance of anxiety in IBS outpatients: relation to bowel symptoms and final diagnosis. Gut 2002;52(Suppl 1):A86.
3. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999;45(Suppl 2):1143-1147.
4. Dunlop SP, Jenkins D, Spiller RC. Distinctive histological patterns of chronic inflammatory cells in rectal biopsies of patients with different clinical subtypes of IBS. Gastroenterology 2002;122(Suppl 1):A60.
5. Stewart GT. Post-dysenteric colitis. Br Med J 1950;i:405-409.
6. Chaudhary NA, Truelove SC. The irritable colon syndrome. QJM 1962;123:307-322.
7. McKendrick MW, Read NW. Irritable bowel syndrome - post Salmonella infection. J Infect 1994;29:1-3.
8. Gwee KA, Graham JC, McKendrick MW, Collins SM, Marshall JS, Walters SJ, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996;347:150-153.
9. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, et al. The role of psychological and biological factors in postinfective gut dysfunction, Gut 1999;44:400-406.
10. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997;314:779-782 [see comments].
11. Thornley JP, Jenkins D, Neal K, Wright T, Brough J, Spiller RC, Relationship of campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome. J Infect Dis 2001;184:606-609.
12. Parry SD, Barton JR, Welfare MR. Does infectious diarrhoea (ID) predispose people to functional gastro-intestinal disorders (FGIDs)? A prospective community case-control study. Gut 2002;50:1.
13. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999;318:565-566.
14. Wheeler JG, Sethi D, Cowden JM, Wall PG, Rodrigues LC, Tompkins DS, et al. Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. The Infectious Intestinal Disease Study Executive. Br Med J 1999;318:1046-1050.
15. Huerta C, Garcia Rodriguez LA, Wallander MA, Johansson S. Risk of irritable bowel syndrome among asthma patients. Pharmacoepidemiol Drug Saf 2002;11:31-35.
16. Georges-Courbot MC, Cassel-Beraud AM, Gouandjika I, Monges J, Georges AJ. A cohort study of enteric campylobacter infection in children from birth to two years in Bangui (Central African Republic). Trans R Soc Trop Med Hyg 1990;84:122-125.
17. Kapoor KK, Nigam P, Rastogi CK, Kumar A, Gupta AK. Clinical profile of irritable bowel syndrome. Indian J Gastroenterol 1985;4:15-16.
18. Wei X, Chen M, Wang J. The epidemiology of irritable bowel syndrome and functional constipation of Guangzhou residents. Zhonghua Nei Ke Za Zhi 2001;40:517-520.
19. Pan G, Lu S, Ke M, Han S, Guo H, Fang X. Epidemiologic study of the irritable bowel syndrome in Beijing: stratified randomized study by cluster sampling. Chin Med J (Engl) 2000;113:35-39.
20. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002;51:410-413.
21. Drossman DA, McKee DC, Sandier RS, Mitchell CM, Cramer EM, Lowman BC, et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 1988;95:701-708.
22. Anand AC, Reddy PS, Saiprasad GS, Kher SK. Does non-dysenteric intestinal amoebiasis exist? Lancet 1997;349:89-92.
23. Chan J, Gonsalkorale W, Perrey M. IL-10 and TGF-beta phenotype in irritable bowel syndrome: evidence to support an inflammatory component (abstr). Gastroenterology 2000;118:A184.
24. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999;42:1101-1108.
25. Blaser MJ, Berkowitz ID, LaForce FM, Cravens J, Reller LB, Wang WL. Campylobacter enteritis: clinical and epidemiologic features. Ann Intern Med 1979;91:179-185.
26. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804-811.
27. Playford RJ, Domin J, Beacham J, Parmar KB, Tatemoto K, Bloom SR, et al. Preliminary report: role of peptide YY in defence against diarrhoea. Lancet 1990;335:1555-1557.
28. Bjarnason I, Maxton D, Reynolds AP, Catt S, Peters TJ, Menzies IS. Comparison of four markers of intestinal permeability in control subjects and patients with coeliac disease. Scand J Gastroenterol 1994;29:630-639.
29. Chavez AM, Menconi MJ, Hodin RA, Fink MP. Cytokine-induced intestinal epithelial hyperpermeability: role of nitric oxide. Crit Care Med 1999;27:2246-2251.
30. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002;97:2000-2004.
31. Barbara G, De Giorgio R, Deng Y, Vallance B, Blennerhassett P, Collins SM. Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. Gastroenterology 2001;120:1729-1736.
32. Linden DR, Sharkey KA, Mawe GM. Inflammation is associated with an increased availability of serotonin from enterochromaffin cells in the guinea pig distal colon. FASEB J 2002;16:A890.
33. Wheatcroft J, Wakelin D, Jenkins D, Spiller RC. Increased enteroendocrine cell numbers in the Trichinella spiralis infected mouse model of post-infectious bowel dysfunction. Gastroenterology 2002;122(Suppl 1):A162.
34. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-468.
35. Camilleri MJ, McKinzie S, Burton D, Thomforde GM, Zinsmeister AR, Bouras EP. Prucalopride accelerates small bowel and colonic transit in patients with chronic functional constipation (FC) or constipation-predominant irritable bowel syndrome (C-IBS). Gastroenterology 2000;118:A845.
36. Kozlowski CM, Green A, Grundy D, Boissonade FM, Bountra C. The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 2000;46:474-480.
37. Mossner R, Lesch KP. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun 1998;12:249-271.
38. Cann PA, Read NW, Brown C. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut 1983;24:405-411.
39. Szajewska H, Kantecki M, Albrecht P, Antoniewicz J. Carbohydrate intolerance after acute gastroenteritis - a disappearing problem in Polish children. Acta Paediatr 1997;86:347-350.
40. Parry SD, Barton JR, Welfare MR. Is lactose intolerance implicated in the development of post-infectious bowel symptoms in previously asymptomatic people? Gut 2002;50:301.
41. Lisker R, Aguilar L, Zavala C. Intestinal lactase deficiency and milk drinking capacity in the adult. Am J Clin Nutr 1978;31:1499-1503.
42. Perk G, Ackerman Z, Cohen P, Eliakim R. Lymphocytic colitis: a clue to an infectious trigger. Scand J Gastroenterol 1999;34:110-112.
43. Miehlke S, Heymer P, Bethke B, Bastlein E, Meier E, Bartram HP, et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 2002;123:978-984.
44. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503-3506.
45. Sanders DS, Carter MJ, Hurlstone DP, Pearce A, Ward AM, McAlindon ME, et al. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 2001;358:1504-1508.
46. Lai Ping SA, Mayer L. Gastrointestinal manifestations of primary immunodeficiency disorders. Semin Gastrointest Dis 1997;8:22-32.
47. Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 2000;47(Suppl 2):111-1119.
48. Parker TJ, Naylor SJ, Riordan AM, Hunter JO. Management of patients with food intolerance in irritable bowel syndrome: the development and use of an exclusion diet. J Hum Nutr Diet 1995;8:159-166.
49. Barrow L, Steed KP, Spiller RC, Maskell NA, Brown JK, Watts PJ, et al. Quantitative, noninvasive assessment of antidiarrhoeal actions of codeine using an experimental model of diarrhea in man. Dig Dis Sci 1993;38:996-1003.
50. Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 1980;79:1272-1275.
51. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984;29:239-247.
52. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl 1987;22:81-84.
53. Myren J, Lovland B, Larssen S-E, Larsen S. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 1984;19:835-843.
54. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-1256.
55. Riberdy-Poitras M, Verrier P, Plourde V, Boivin M, Poitras P. Amitriptylin for the treatment of IBS. Gastroenterology 2000;118: A617.
56. Talley NJ, Phillips SF, Haddad A, Miller LJ, Twomey C, Zinsmeister AR, et al. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990;35:477-480.
57. Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-1159.
58. Prior A, Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993;7:175-180.
59. Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998;42:42-46.
60. Williams AJK, Merrick MV, Eastwood MA. Idiopathic bile acid malabsorption - a review of clinical presentation, diagnosis, and response to treatment. Gut 1991;32:1004-1006.
61. Niaz SK, Sandrasegaran K, Renny FH, Jones BJ. Postinfective diarrhoea and bile acid malabsorption. J R Coll Physicians Lond 1997;31:53-56.
62. Tazume S, Ozawa A, Yamamoto T, Takahashi Y, Takeshi K, Saidi SM, et al. Ecological study on the intestinal bacterial flora of patients with diarrhea. Clin Infect Dis 1993;16:S77-S82.
63. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998;352:1187-1189.
64. Isolauri E, Kaila M, Mykkanen H, Ling WH, Salminen S. Oral bacteriotherapy for viral gastroenteritis. Dig Dis Sci 1994;39:2595-2600.
65. Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 2002;47:2625-2634.
66. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebocontrolled crossover study. Dig Liver Dis 2000;32:294-301.
67. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-1238.
68. Fine KD, Lee EL. Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis. Gastroenterology 1998;114:29-36.
69. Riordan SM, McIver CJ, Duncombe VM, Thomas MC, Nagree A, Bolin TD. Small intestinal bacterial overgrowth and the irritable bowel syndrome. Am J Gastroenterol 2001;96:2506-2508.
70. McKendrick MW. Post Salmonella irritable bowel syndrome-5-year review. J Infect 1996;33:170-171.
71. Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet 1987;1:963-965.
72. Bennett EJ, Tennant CC, Piesse C, Badcock CA, Kellow JE. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998;43:256-261.